E6 and E7 antibody levels are potential biomarkers of recurrence in patients with advanced-stage human papillomavirus-positive oropharyngeal squamous cell carcinoma

Matthew E. Spector, Assuntina G. Sacco, Emily Bellile, Jeremy M.G. Taylor, Tamara Jones, Kan Sun, William C. Brown, Andrew C. Birkeland, Carol R. Bradford, Gregory T. Wolf, Mark E. Prince, Jeffrey S. Moyer, Kelly Malloy, Paul Swiecicki, Avraham Eisbruch, Jonathan B. McHugh, Douglas B. Chepeha, Laura Rozek, Francis P. Worden

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Purpose: There is a paucity of biomarkers to predict failure in human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) following curative therapy. E6/E7 viral oncoproteins are constitutively expressed in HPV+ tumors and highly immunogenic, resulting in readily detected serum antibodies. The purpose of this study is to determine whether serum E6 and E7 antibody levels can potentially serve as a biomarker of recurrence in patients with HPV+OPSCC. Experimental Design: We evaluated E6/E7 antibody levels in patients with previously untreated, advanced stage (III, IVa-b), HPV+OPSCC receiving definitive chemoradiation under a uniform protocol from 2003 to 2010. Baseline and longitudinal serum samples were obtained from our archived repository. E6/E7 serum levels were measured using a glutathione-S-transferase capture ELISA and quantified by approximating the area under the dilution curve, and were analyzed using ANOVA and linear mixed model for longitudinal analysis. Results: We compared 22 HPV+OPSCC patients who developed recurrence with 30 patients who remained disease-free. There were no differences in T classification, N classification, disease subsite, or smoking status between the groups. In a longitudinal analysis, recurrent patients had significantly higher E6 and E7 serum antibody levels than the nonrecurrent patients over the follow-up period (P = 0.02 and P = 0.002, respectively). Patients who recurred had a lower clearance of E7 antibody than patients who remained disease-free (P = 0.0016). Conclusions: Patients with HPV+OPSCC whose disease recurs have a lower clearance of E6 and E7 antibodies than patients who do not have recurrence. The ratio of E7 antibody at disease recurrence compared with baseline is potentially a clinically significant measurement of disease status in HPV+OPSCC.

Original languageEnglish (US)
Pages (from-to)2723-2729
Number of pages7
JournalClinical Cancer Research
Volume23
Issue number11
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'E6 and E7 antibody levels are potential biomarkers of recurrence in patients with advanced-stage human papillomavirus-positive oropharyngeal squamous cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Spector, M. E., Sacco, A. G., Bellile, E., Taylor, J. M. G., Jones, T., Sun, K., Brown, W. C., Birkeland, A. C., Bradford, C. R., Wolf, G. T., Prince, M. E., Moyer, J. S., Malloy, K., Swiecicki, P., Eisbruch, A., McHugh, J. B., Chepeha, D. B., Rozek, L., & Worden, F. P. (2017). E6 and E7 antibody levels are potential biomarkers of recurrence in patients with advanced-stage human papillomavirus-positive oropharyngeal squamous cell carcinoma. Clinical Cancer Research, 23(11), 2723-2729. https://doi.org/10.1158/1078-0432.CCR-16-1617